Shares of LivaNova PLC (NASDAQ:LIVN – Get Free Report) have been given a consensus rating of “Buy” by the six research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $70.80.
Several brokerages have issued reports on LIVN. Needham & Company LLC raised their price objective on shares of LivaNova from $72.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Robert W. Baird raised LivaNova from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $55.00 to $66.00 in a report on Tuesday, September 17th. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, Stifel Nicolaus increased their price objective on LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th.
Read Our Latest Analysis on LIVN
LivaNova Stock Down 0.9 %
LivaNova (NASDAQ:LIVN – Get Free Report) last released its earnings results on Wednesday, July 31st. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.15. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. The business had revenue of $318.60 million during the quarter, compared to analysts’ expectations of $305.05 million. Analysts anticipate that LivaNova will post 2.58 EPS for the current fiscal year.
Hedge Funds Weigh In On LivaNova
Several hedge funds have recently bought and sold shares of the company. Hexagon Capital Partners LLC raised its holdings in shares of LivaNova by 117.8% during the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock worth $37,000 after buying an additional 370 shares in the last quarter. Fifth Third Bancorp lifted its holdings in shares of LivaNova by 97.1% in the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after acquiring an additional 332 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in shares of LivaNova in the 1st quarter valued at approximately $84,000. Canada Pension Plan Investment Board bought a new stake in shares of LivaNova during the 2nd quarter valued at approximately $88,000. Finally, Acadian Asset Management LLC acquired a new position in LivaNova during the 1st quarter worth approximately $94,000. 97.64% of the stock is owned by institutional investors.
About LivaNova
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Further Reading
- Five stocks we like better than LivaNova
- What is a Stock Market Index and How Do You Use Them?
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Why Invest in High-Yield Dividend Stocks?
- MarketBeat Week in Review – 9/16 – 9/20
- How to Use Stock Screeners to Find Stocks
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.